A director at Salesforce Inc bought 3,882 shares at 257.283USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Ernexa Therapeutics Closes New Funding Round Comes on the heels of company’s rebranding and new strategic direction, advancing its lead program in ovarian cancer CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purchase shares of common stock), at a purchase price of $...
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering commitment to patient impact,“Breaking Through Defenses, Delivering Hope” CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.